SAN DIEGO, March 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. today announced it will release fourth quarter and full year 2006 financial results after the financial markets close on Thursday, March 15, 2007. ADVENTRX management will host an investment-community conference call to discuss the results and provide a corporate update on Thursday, March 15, 2007 at 4:30 p.m. Eastern Time.
Evan M. Levine, Chief Executive Officer and Gregory P. Hanson, Senior Vice President and Chief Financial Officer are scheduled to lead the call and will be joined by other members of the Company’s senior management to discuss the quarter’s and year’s results and to take investors’ questions.
Those interested in listening to the conference call live via the Internet may do so by visiting the “Investors” section of ADVENTRX’s website at www.adventrx.com. Replays of the webcast will be available for 30 days, and a phone replay will be available through April 16, 2007 by dialing 888-203-1112 and entering the passcode 5166464.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism and bioavailability, excessive toxicity and treatment resistance. The Company’s lead product candidate, ANX-510 (CoFactor), is in pivotal Phase III and Phase IIb clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase II clinical trial for the treatment of advanced breast cancer. More information can be found on ADVENTRX’s web site at www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors that, if they do not materialize or prove to be accurate, could cause ADVENTRX’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such forward-looking statements are made based on management’s current expectations and beliefs and should not be regarded as a statement or representation by ADVENTRX that any of its plans, including its anticipated milestones, will be achieved on time or at all. The potential risks and uncertainties that could cause actual results to differ materially include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient capital to fund the projects necessary to meet its anticipated or stated goals and milestones; the potential to attract a strategic partner and the terms of any related transaction; the ability to timely enroll subjects in ADVENTRX’s current and anticipated clinical trials; the potential for CoFactor and ADVENTRX’s other product candidates to receive regulatory approval for one or more indications on a timely basis or at all, and the uncertain process of seeking regulatory approval; other difficulties or delays in developing, testing, manufacturing and marketing of and obtaining regulatory approval for CoFactor or ADVENTRX’s other product candidates; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings; the scope and validity of patent protection for CoFactor and ADVENTRX’s other product candidates; and other risks and uncertainties more fully described in ADVENTRX’s press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX’s public filings with the Securities and Exchange Commission are available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All forward-looking statements are qualified in their entirety by this cautionary statement and ADVENTRX assumes no obligation to revise or update any forward-looking statement, including as set forth in this press release, to reflect events or circumstances arising after the date on which it was made.
ADVENTRX Pharmaceuticals, Inc.
CONTACT: Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc.,+1-858-552-0866; or Media, Amy Martini of WeissComm Partners,+1-212-301-7233, for ADVENTRX Pharmaceuticals, Inc.
Web site: http://www.adventrx.com/
Company News On-Call: http://www.prnewswire.com/comp/920134.html /
